Эффективность терапии больных с генерализованным тревожным расстройством с учетом плацебо-реактивности
Диссертация
Несмотря на большой спектр препаратов (анксиолитики, антидепрессанты, нейролептики), использующихся при терапии ГТР, проблемы лечения этих состояний остаются по-прежнему актуальными. Недостаточная изученность механизмов генерализованной тревоги предопределяет преимущественно эмпирический подход к выбору того или иного препарата для лечения этого состояния. До сих пор не разработаны методики… Читать ещё >
Список литературы
- Аведисова А.С. Социально-экономические стрессы: выявляемость и распространенность пограничных психических расстройств. Социальная и судебная психиатрия: история и современность. М., 1996. -С. 7−9.
- Аведисова А.С. Тревожные расстройства. в кн.: Психические расстройства в общемедицинской практике и их лечение. — под ред. Ю. А. Александровского. — М.: ГЭОТАР-МЕД. — 2004. — С.66−73.
- Аведисова А.С., Бочкарев В. К., Люпаева Н. В. Соотношение плацебо-эффекта и действия антидепрессантов по данным ЭЭГ. Журн. невропатол. и психиатрии им. С. С. Корсакова. 2004, Т. 104, № 11.
- Аведисова А.С., Чахава В. О., Люпаева Н. В. Плацебо-эффект в психиатрии. Психиатрия и психофармакотерапия. 2004, Т.6, № 2.
- Александровский Ю.А. Состояния психической дезадаптации и их компенсация. М.:Наука. — 1976. -272с.
- Александровский Ю.А. Начальные проявления невротических расстройств. Клин. мед. — 1988. — 9. — С.58−64.
- Александровский Ю.А. Пограничные психические расстройства. Изд. 2-е. Ростов-на-Дону: Феникс, 1997. — 579с.
- Александровский Ю.А., Барденштейн Л. М., Аведисова А. С. Психофармакотерапия пограничных психических расстройств. М.: ГЭОТАР МЕД. — 2000. — 250с.
- Асатиани Н.М. Некоторые особенности клиники и патогенеза невроза навязчивых состояний с психастении. Клиническая динамика неврозов и психопатий. — Л. — 1967. -С.36−58.
- Белянчикова М.А. и соавт. Препарат атаракс в амбулатолрной терапии тревожных состояний, в кн.: Тревога и обсессии. Под ред. А. Б. Смулевича.-М. 1998. — С279−285.
- Бобров А.Е., Кулыгина М. А. Дифференцированная психотерапия тревожных расстройств и клинико-психологические характеристикикогнитивного личностного стиля, в кн.: Тревога и обсессии. Под ред. А. Б. Смулевича.- М. 1998. — С.306−317.
- Вальдман А.В., Александровский Ю. А., Жердев В. В. Биологические основы индивидуальной психофармакотерапии. 7-й Всесоюзный съезд невропатологов и психиатров. М., 1981. — Т. 1. — С. 28−31.
- Вейн A.M., Дюкова Г. М., Воробьева О. В., Данилов А. Б. Панические атаки. СПб.: ООО «Институт медицинского маркетинга», 1997. -304с.
- Жане П. Неврозы. М. — 1911.
- Завьялов В.Ю. Необъявленная психотерапия. М.: Академический Проспект, 1999.-250 с.
- Карвасарский Б.Д. Психотерапия. М.:Медицина. — 1985. — 303с.
- Карвасарский Б.Д. Неврозы: Руководство для врачей. М.:Медицина.- 1980. -448с.
- Краснов В.Н., Гурович И. Я. и соавт. Клиническое руководство: модели диагностики и лечения психических и поведенческих расстройств. М 2000: 104−105.
- Лапин И.П. Личность и лекарство. Введение в психологию фармкотерапии. -СПб., Изд. «Деан», 2001. 416 с.
- Лапин И.П. Плацебо-эффект и практика реабилитации психических больных. В кн.: Фармако-терапевтические основы реабилитации психически больных. М.: Медицина, 1989. — С. 242−255.
- Литвак М.Е. Неврозы. Ростов-на-Дону. — 1993.
- Личо A.E. Неврозы и неврозоподобные расстройства при акцентуациях характера у подростков. в кн.: IV симпозиум детских психиатров социалистических стран. — М. — 1976. — С.70−76
- МакГлинн Т.Дж., Меткалф Г. Л. Диагностика и лечение тревожных расстройств. Руководство для врачей. 119с. — Copyright 1989 by American Psychiatric Press, Inc.
- Международная классификация болезней (10 пересмотр). Классификация психических и поведенческих расстройств (Клинические описания и указания к диагностике). ВОЗ. СПб.: «Адис», 1994.
- Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб. 1995. 565 с.
- Мясищев В.Н. Личность и неврозы. Л., Изд-во ЛГУ. — 1960. -425с.
- Свядощ A.M. Неврозы и их лечение. М.:Медицина. — 1982. -368с.
- Смулевич А.Б. Психогенные заболевания. Психопатии // Руководство по психиатрии. М. — 1983. -Т.2. -С.342−441.
- Смулевич А.Б., Тхостов А. Ш., Иванов С. В., Андреев A.M. Лечение тревожно-фобических расстройств: непосредственный и отдаленный результа, прогноз эффективности. в кн.: Тревога и обсессии. Под ред. А. Б. Смулевича.- М. — 1998. — С.158−187.
- Смулевич А.Б. Депрессии в общемедицинской практике М. 2000. -160с.
- Ястребов Д.В., Колюцкая Е. В. Терапия социальных фобий (клинические предикторы эффективности моклобемида). в кн.: Тревога и обсессии. Под. ред. АБ. Смужвича. — М. — 1998. — С.234−246.
- Alnaes R, Torgersen S. (1990) DSM-III personality disorders among patients with major depression, anxiety disorders and mixed conditions. Journal of Nervous and Mental Disease, 178,693−698.
- American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental Disorders, 3d ed. (DSM-III). Washington, DC: American Psychiatric Association.
- American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3d ed. revised (DSM-III-R). Washington, DC: American Psychiatric Association.
- American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association.
- Angst J, Dobler-Mikola A. Eur Arch Psychiat Neurol Sci 1985. 235:179 186.
- Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatr Scand 1991- 84: 446−52.
- Ansseau M, Doumont A, Thiry D, et al (1985). Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. Psychopharmacology 87,130.
- Ballenger JC Treatment of anxiety disorders to remission J Clin Psychiatry (2001) 62 (suppl. 12) P.5−9.
- Barlow DH, Lerner JA, Esler JL. Behavioral health care in primary care settings: Recognition and treatment of anxiety disorders. In: Health Psychology Through the Life Span: Practice and Research Opportunities. -АРА: Washington, DC, 1996.
- Barlow DH. Anxiety and its disorders. The nature and treatment of anxiety and panic. New Ycrk: Guilford Press, 1988.
- Barranco SF, Bridger W. Treatment of anxiety with oral hydroxyzine: An overview. Current Therapeutic Research (1977) 22:217−27.
- Beecher H. K // JAMA. 1995 — Vol. 159. — P 1602−1606.
- Benson H. The relaxation response. NY, Marrow, 1975.
- Beson H., Friedman R. Harnessing the power of placebo effect and renaming it «Remembered weiiness» // Ann. Rev. Med.: Selected Topics Clin./Sci. 1996. V. 47. P. 193−199.
- Beutler L.E. / Prevent, and Treat. -1998. Vol. 1. — June. — Ait. 0003c.
- Bienenfeld L. et al. The placebo effect in cardiovascular disease // Amer. Heart J. 1996. V. B2. P. 1207−1221.
- Borkovec TD, Lyonfields JD, Wiser SL, Deihl L. The role of worrisome thinking in the suppression of cardiovascular response to phobic imagery. -Behav Res Ther (1993) 31:321−4.
- Breslow IH. Evaluation of hydroxyzine pamoate concentrate as an ataractic: double-blind cross-over study in a neurotic male prison group. -Current Therapeutic Research (1968) 10:421−7.
- Brody H. The Doctor as Therapeutic Agent: A Placebo Effect Research Agenda. The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2000. P.77−92.
- Brown GW, Harris TO, Eales MJ. Social factors and comorbidity of depressive and anxiety disorders. Br J Psychiatry 1996- 168 (suppl 30): 5057.
- Brown WA The Placebo Effect. Scientific American. 1998. Vol. 278. p.90.95.
- Brown ТА, Barlow DH, Liebowitz MR. The empirical basis of generalized anxiety disorder. Am J Psychiatry 1994- 151: 1272−80.
- Butler G, Gelder M, Hibbert G, et al (1987). Anxiety management -developing effective strategies. Behav Res Therap 25:517−22.
- Butler G., Fem®l M., Robson P., GelcferM., Canparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder., I consult. Clin, ftychol (1991) 59:167−175.
- Cannon WB. The wisdom of the body. NY. -1931.
- Carter CS, Maddock RJ. Chest pain in generalized anxiety disorder. IntJ Psychiatry Med 1992- 22: 291−98.
- Castillo A, Sotillo C, Mariateegui J (1987). Alprazolam compared to clobazam and placebo in anxious outpatients. Neuropsychobiology 18,189.
- Chassan JB., Researt design in clinical psychology and psychiatry, Soc. Psychietry, 1980:15, 43−55
- Coryell W, Endicott J, Andersen N et al. Am J Psychiat. 1988. — 3:293 300.
- Coryell W, Winokur G. The clinical management of anxiety disorders., eds. New York: Oxford University Press, 1991
- Cowley DS, Roy-Byrne PP, Hommer DW et al. Benzodiazepine sensitivity in anxiety disorders. Biol Psychiatry 1991- 29:57A.
- Deakin JFW. A review of the clinical efficacy of 5-HTla agonists in anxiety and depression. J Psychopharmacol (1993) 7:283−9.
- Deffenbacher JL, Suinn RM. Generalized anxiety syndrome. In: Anxiety and Stress Disorders, Cognitive-Behavioral Assessment and Treatment. -NY, Guilford Press. 1987. pp352−360.
- DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry 2000 Feb-61(2): 91−4.
- Derivan AT, Entsuah R, HaskinsJT, Rudolph R. Double-blind, placebo -controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder. Eur Neuropsychopharmacology 1998- 8 (suppl):S26.
- Do Amaral J.R., R. M. E. Sabbatini. Placebo Effect: The Power of the sugar pill. 2001.
- Docherty JP, Fiester SJ, Shea T: Syndrome diagnosis and personality disorder, in Frances AJ, Hales RE (eds): Psychiatry Update: American Psychiatric Association Annual Review, vol 5. Washington, DC, American Psychiatric Press, 1986, pp 315−255.
- Du Pont RL, Rice DP, Miller LS et al. Economic costs of anxiety disorders. Anxiety 1996- 2:167−72.
- Durham RC, Allan T, Hackett С A. On predicting improvement and relapse in generalized anxiety disorder following psychotherapy (1997) British Journal of Clinical Psychology, 36, 101−119.
- Durham RC, Mirphy T, Alan T, Rchard K, Treliving LR, Fmton GW. Cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder. Br J Psychiatry 1994- 165:315−23.
- EI-Khayat R, Baldwin D. Artipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. J Psychopharmacol 1998,12:323−329.
- Eison MS. Azapirones: mechanism of action in anxiety and depression. -Drug Ther (1990) 20 (suppl): 3−8.
- Ernst E, Resch KL. Concept of true perceived placebo effects. // BMJ. Vol. 311. August, 1995. p. 551−553.
- Eysenk HJ. The biological basis of personality. Springfield. -C.C.Ttomas. -1967.
- Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients generalized anxiety disorder. J Clin Psychiatry (1982) 43:103−7.
- Fields HL, Price DD. Toward a Neutrobiology of Placebo Analgesia. The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2000. P. 93−116.
- Fisher S, Gremberg RP. Fran placebo to panacea: putting psychiatric drug to the test. 1997. «J. Wiley and Sons».
- Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994- 151: 640−49.
- Frances A, Manning D, Marn D etal. Psychopharmacol (1992) 106:82−86.
- Freud S. The justification for detaching from neurasthenia c. particular syndrome: the anxiety neurosis. Collected Papers, vol.1, 76−106. London: Hogarth Press, 1953. Originally published in 1894.
- Garvey MJ, Cook B, Noyes R Jr. The occurrence of a prodrome of generalized anxiety in panic disorder. Gbmpr Psychiatry 1988- 29: 445−449.
- Gasperini, M, Battaglia, M, Diaferia, G et al. Personality features related to generalized anxiety disorders. (1990) Comprehensive Psychiatry, 31, 363 368.
- Gelenberg A. J., R. B. Lydiard, R. L. Rudolph, L. Aguiar, J. T. Haskins, E. Salinas, MD. Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder. JAMA. -2000−283:3082−3088.
- German JM. Comorbid depression and anxiety spectrum disorders. Depr Anxiety 1996/1997- 4: 160−68.
- Gliedman L. H., Nash E.H., Imber S. D. Et al. Reduction of symptoms by pharmacologically inert substances and by short-term psychotherapy //Arch. Neurol. Psychiatry. 1958. V. V. P. 345 351.
- Goldberg RJ. Anxiety reduction by selfregulation: Theory, practice and evaluation. Ann Intern Med (1982) 96:483−487.
- Gorman JM, Gorman LK. Drug treatment of social phobia. J Affective Disord (1987) 13:183−192.
- Hahn RA. The Nocebo Phenomenon: Scope and Foundations. The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2000. P.56−76.
- Hamilton M. The borderline between anxiety and depression. -Medidact., Leusden, Netterland. 1988:11−21.
- Hantouche E, FerreriM. Эффективность гидроксизина при генерализованной тревоге (2002). media/psycho/0004/124.shtml
- Hecker Е. Uber larviete und abortive Angstzustande bei neurasthenie. -Berlin. 1893.
- Henderson CE. Phcebo Effects Prove the Value of Suggestion.
- Heninger G., DiMascio A., Klerman G. L. Personality factors in valiability of response to phenothiazines //Amer. J. Psychiatry. 1965. V. 21. P. 1091 -1094.
- Herz A. The role of opioid peptides in placebo-induced effects // Pharmacopsychiat. 1986. V. 19. P. 339−340.
- Hoehn-Saric R, McLeod DR, Zimmerli WD (1988). Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 49,293.
- Hoehn-Saric R. Characteristics of chronic anxiety patients. In: Klein DF, Rablin J, eds. Anxiety: New Research and Changing Concepts. New York, NY: Raven Press, 1981.
- Hoehn-Saric R., McLeod D.R.Depression and anxiety: is there a common etiology? In: der Boer J.A. Sitsen J.M. eds. Handbook of Depression and Anxiety. New-Ycrk: Marcel Dekker- 1994: 119−132.
- Jacobson E. Progressive relaxation. Chicago. -1929.
- Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of placebo effect // Psychosomatic medicine. 1991. V. S. P. 14−152.
- Kahn RJ, McNair DM, Lipman RS et al. Imipramine and chloidiazepoxide in depressive and anxiety disorders: Efficacy in anxious outpatients. Arch Gen Psychiatry 1986- 43: 79−85.
- Kane FJ, Harper RG, Wittels E. Angina as a symptom of psychiatric illness. South Med J 1988- 81: 1412−16.
- Kendler KS Major depression and generalized anxiety disorder. Same genes, (partly) different environments revisited. BrJ Psychiatry 1996- 168 (suppl 30): 68−75.
- Kirsch I, Weixel L Double-blind versus deceptive administration of a placebo//Behavioral Neuroscience. 1988. V. 102. P. 319 323.
- Kirsch I. Specifying Nonspecifics: Psychological Mechanisms. / The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2GOO. P.166−186.
- Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964- 5: 397−408.
- Kurland A.A.The drug placebo: its psychodynamic and conditioned reflexaction //Behav. Sci. 1957. V.2 P. Б1−110.
- Lader MH, Ron M, Petursson H. Computed axial brain tomography in long-term benzodiazepine users. Psychol Med (1984) 14:203−6.
- Lasagna L. et al. Study of Placebo Response. Amer.J.Med. 1954. Vol. 16. p.770−785.
- Levine J.D., Gorden N.C., Fields H.L. The mechanism of placebo analgesia //Lancet. 1978. II. P. 63.
- Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder. Arch Gen Psychiatry. 2005- 62(2): 190 — 198.
- Loebel A.D., Hide T.S., Dunner D.L.Early placebo response in anxious and depressed patients. J. Clin. Psychiatry. 1986. — V. 47. — № 5. — P. 230 233.
- Logue MB, Thomas AM, Barbee JG et al. Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. JPsychiatr Res 1993- 27: 55−59
- Lydiard RB Anxiety and the irritable bowel syndrome: Psychiatric, medical, or both? J Clin Psychiatry 1997- 58 (suppl 3): 51−58.
- Mancuso DM, Townsend MH, Mercante, DE (1993) Long-term follow-up of generalized anxiety disorder. Gbmprehensive Psychiatry, 34,441−446.
- Marks I. Feas, Phobias and Rituals. NY, Oxford University Press, 1987
- Massion AO, Eyck IR, Stea MT, Philips KA, Warshaw MG, Keler MB Personality Disorders and Time to Remission in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder. ArchGen Psychiatry. 2002−59:434−440.
- Mericangas KR, Angst J. Eur Arch Psychiatry Clin Neurosci (1995) 244:297−303.
- Moller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J4 Rychopharmacol 2001 Feb-21(1):59−65.
- Morris DB Placebo, Pain, and Relief: A Biocultural Model. / The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2GD0. P. 187−207.
- Nagy A. Acta Psychiatr Scand Suppl 1987. -76. -335: 47−55.
- Nutt DJ, Bell CJ, PotokarJP. Drug-treatment of chronic anxiety. Bailliere’s Clin Psychiatry 1995- 1: 565−94.
- Nutt DJ, K. Rickels, D.J.Stein- Generalized Anxiety Disorder. Martin Dunitz Ltd, 2002.
- Nutt DJ. The psychopharmacology of anxiety. Br J Hosp Med 1996- 55: 187−91.
- Nutzinger DO, Zapotocki HG. Psychopathology (1985). 18- 2/3:155 162.
- Pancheri L. et al. II placebo come farmaco. Parte 2. II trattamento della depressione. Riv. Psichiat. 1991. V. 26. N.l. P. 1−11. Цит по РЖ 04 Биология. 1991. 10.80.87.
- Perry P, Bever-Stille K. (1996). Benzodiazepine Treatment of Generalized Anxiety Disorder http://www.vh.org/adult/provider/psvchiatry/CPS/36.html
- Petracca A, Nisita C, McNair D, et al. (1990). Treatment of generalized anxiety disorder. Preliminary clinical experience with buspirone. J Clin Psychiatry 51
- Piccinelli M. Comorbidity of depression and generalized anxiety: is there any distinct boundary? Curr Opin Psychiatry 1998:11:57−60.
- Piercy M.A. et. al. Placebo response in anxiety disorders. Ann. Pharmacother. -1996. -V. 30. P. 1013−1019.
- Price D. D., H.L. Fields. The Contribution of Desire and Expectation to Placebo Analgesia: Implications for New Research Strategies. / The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2000. P. l 17−137.
- Quitkin F. M. Placebos, Drug Effects, and Study Design: A Clinician’s Guide. //American Journal of Psychiatry 156:6, June 1999.
- Raskin M, Bali L, Peeke H. Muscle biofeedback and transcendental meditation: a controlled evaluation of efficacy in the treatment of chronic anxiety. Arch Gen Psychiatry 1980- 37: 93−97.
- Rickels K, Case G, Downing RW, et al (1983). Long-term diazepam therapy and clinical outcome. JAMA 250,767.
- Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. Arch Gen Psychiatry 1993- 50: 884−95.
- Rickels K, Schweizer E, Case GC and Greenblatt DJ. Long-term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990- 47: 899−907.
- Rickels K, Schweizer E, De Martinis N et al. Gepirone and diazepam in generalized anxiety disorders: a placebo-controlled trial. J Clin Psychopharmacol 1997- 17:272−77.
- Rosenberg NK, Mellerg^rd M, Rosenberg R, BeckP, Otosson JO. Characteristics of panic disorder patients responding to placebo. Acta Psychiatr Scand (Suppl) 1991. 3®:33−8.
- Ross CA, Matas M (1987). A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. CanJ Psychiatry 32,351.
- Salkovskis PM, Campbell P. Thought suppression induces intrusion in naturally occurring negative intrusive thought. Behav Res Ther (1994) 32:1−8.
- Sanderson WC, DiNardo PA, R^ee RM, Barlow DH. Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. J Abnorm Psychol 1990−99:308−12.
- Sanderson WC, Wetzler S. Chronic Anxiety. Generalized anxiety disorder and mixed anxiety-depression/ Guilford Press, New Ycrk, 1991
- Schweitzer E, Rickels K. The long-term management of generalized anxiety disorder: issues and dilemmas. J Clin Psychiatry 1996- 57 (suppl 7): 9−14.
- Schweizer E., Rickels K. Placebo response in generalized anxiety: it’s effect on the outcome of clinical trials. J. Clin. Psychiatry. 1997. — V. 58. -Suppl. 11. — P. 30−39.
- Shapiro AK The placebo effect. Principles of Psychophaimacology -Academic press. N.Y. -1978. — P. 441−459.
- Shapiro AK, Shapiro E The Placebo: Is it Much Ado about Nothing? / The Placebo Effect. An Interdisciplinary Exploration. Harvard University Press, Cambridge, Mass., 2GOO. P. 1236.
- Shapiro AK, Shapiro E. The powerful placebo. From ancient priest to modern physician. The John Hopkins University Press. — Baltimor and London. -1997. -280p.
- Shapiro AK, Stuening EL, Shapiro E, et al (1982). Diazepam: How much better than placebo? J Psychiat Res 17,51−73.
- Shear MK, Cooper AM, Klerman GL, Busch FN, Shapiro Т. A Psychodinamic model of panic disorder. Am J Psychiatry. — 1993. — V.50. — 6:859−866.
- Solomon K., Hart R (1978). Pitfalls and prospects in clinical research on antianxiety drugs: benzodiazepines and placebo a review. J Clin Psych 39,823.
- Sperry L. Psychopharmacology and psychotherapy. Strategies for maximizing treatment outcomes. 1995. New York. Brunner/Mazel. 194p.
- Stahl SM. Mixed depression and anxiety: serotonin 1A receptors as a common pharmacologic link. J Clin Psychiatry 1997- 58 (suppl 8): 20−26.
- Stern RS. Behavioral Techniques. London. — Academic Press. — 1978.
- Taiminen T. et al. Is positive placebo response in chronic schizophrenia investigator dependent? //J. Nevr. Ment. Disease. 1997. V. 185. P. 644 645.
- TyrerP Murphy S et al (1988). The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 2:235−40.
- Tyrer P, Owen R (1984). Anxiety in primary care: is short-term drug treatment appropriate? J Psychiat Res 18,73.
- Weiss BL. Controlled comparison of trifluoperazine and chlordiazepoxide in the treatment of anxiety. Curr Tber Res 1997−22:635−43.
- Wittchen HU, Zhao S, Kessler RC et al. DSM-III-R Generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994- 51: 355−64.
- Wulsin LR, Arnold ML, Hillard JR. Axis I disorders in E.R. patients with atypical chest pain, bit J Psychiatry Med 1991- 21: 37−46.
- Wurthmann C, Klieser E, Lehman E. Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder. Prog Neuropsychopharm Biol Psychiatry 1997- 21: 601−09.
- Yonkers KA, Warshaw MG, Massion AO et al. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 1996- 168: 308−13.
- Yonkers KA. Factors predicting the clinical course of generalized anxiety disorder. The British Journal of Psychiatry 2000- 176: 544−549.
- Zung WWK. (1987). Effectof clorazepate on depressed mood in anxious patients. J Clin Psychiatry 48:13.